Ambrx Biopharma Net Income 2020-2022 | AMAM

Ambrx Biopharma net income from 2020 to 2022. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Ambrx Biopharma Annual Net Income
(Millions of US $)
2021 $-68
2020 $-17
2019 $-20
Ambrx Biopharma Quarterly Net Income
(Millions of US $)
2022-06-30
2021-12-31 $-68
2021-06-30
2020-12-31
2019-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.071B $0.007B
Ambrx Biopharma Inc. is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. Ambrx Biopharma Inc. is based in SAN DIEGO.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $154.721B 9.45
GSK (GSK) United Kingdom $71.915B 9.49
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.215B 19.14
Ginkgo Bioworks Holdings (DNA) United States $4.249B 0.00
Myovant Sciences (MYOV) United Kingdom $2.615B 0.00
Arcus Biosciences (RCUS) United States $1.532B 23.00
Biohaven (BHVN) United States $1.307B 0.00
Emergent Biosolutions (EBS) United States $0.726B 5.71
ADC Therapeutics SA (ADCT) Switzerland $0.376B 0.00
Enzo Biochem (ENZ) United States $0.067B 0.00
SQZ Biotechnologies (SQZ) United States $0.023B 0.00
Gelesis Holdings (GLS) United States $0.022B 0.00